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Abstract
Background: Although immunoglobulin A nephropathy (IgAN) is associated with an increased risk of renal allograft
failure, evidences for its treatment, including renin-angiotensin-aldosterone system blockade (RAASB) usage, remain
limited.
Methods: In this bi-center retrospective cohort study, we included patients who were recently diagnosed with IgAN
through allograft biopsies. We identified their 6-month antihypertensive medication prescriptions and investigated the
association between the medication types, albuminuria changes, and risk of 5-year death-censored-graft-failure (DCGF).
The mixed effect model and cox regression analysis were used.
Results: A total of 464 allograft IgAN patients were included: 272, 38, 33, and 121 patients in the no antihypertensive
medication, single agent RAASB, single agent beta blocker (BB)/calcium channel blocker (CCB), and combination
therapy groups, respectively. High-degree albuminuria after 6 months of allograft IgAN diagnosis was an important
prognostic parameter and a partial mediator for the association between the subgroups and 5-year DCGF. The usage
of single RAASB was associated with decrement of albuminuria from allograft IgAN diagnosis (P for interaction = 0.03).
The single BB/CCB group demonstrated significantly worse prognosis than the single RAASB group (adjusted hazard
ratio, 2.76 [1.09–6.98]; P = 0.03).
Conclusions: In conclusion, RAASB may be beneficial for graft prognosis in early allograft IgAN patients who require
single antihypertensive medication therapy, by means of reducing albuminuria. Further investigation of treatment
strategy in allograft IgAN is warranted.
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Background
Immunoglobulin A nephropathy (IgAN), the most com-
mon primary glomerulonephritis during both the pre- and
post-transplant eras [1–3], has demonstrated better post-
transplant prognosis than other etiologies of end-stage
renal disease (ESRD) in the short-term [4]. However, the
development or recurrence of IgAN in allograft is associ-
ated with an increased risk of graft failure in the long-term
[5, 6]. Although this accelerated graft dysfunction has
been repetitively observed [4, 7, 8], evidence for treatment
strategies of allograft IgAN remains limited. As allograft
glomerulonephritis is one of the major obstacles in the
improvement of long-term graft outcome in modern
transplant medicine, the development of an adequate
management strategy for allograft IgAN would be benefi-
cial for prolonged graft use.
Renin-angiotensin-aldosterone system blockade (RAASB),
which includes angiotensin converting enzyme inhibitors
and angiotensin receptor blockades, has been shown to ef-
fectively suppress the progression of native IgAN [9–12].
However, the benefits of RAASB during post-transplant
periods are still debatable [13–16], although this is mainly
related to a low prescription rate of the medications in the
post-transplantation period [15]. In addition, whether
RAASB usage is associated with better prognosis for primary
glomerulonephritis in allograft, including IgAN [17, 18], is
uncertain, even though a clinical guideline recommend its
usage with a low-grade recommendation level [19].
In this study, we aimed to provide supporting evidence
for the possible benefits of RAASB in allograft IgAN. We
reviewed our retrospective cohort of allograft IgAN
patients and identified their prescribed hypertensive medi-
cation categories [8, 20]. We then compared their progno-
sis in terms of death-censored-graft-failure (DCGF) and
changes in albuminuria levels.
Methods
Study design and study population
This was a retrospective cohort study performed in two
tertiary referral hospitals in Korea. We included trans-
plant recipients who were diagnosed with pathologically
confirmed allograft IgAN. The exclusion criteria were as
follows: 1) patients who were diagnosed with allograft
IgAN before the year 2000, as electronic medical records
did not provide sufficient information related to patients’
prescribed medications during this period, and 2)
patients with follow-up loss or acute graft failure within
6 months from allograft IgAN diagnosis. The remaining
patients were stratified into 4 study groups: 1) those who
did not receive antihypertensive medications (no medi-
cation group); 2) those who received single RAASB-cat-
egory medications (single RAASB group); 3) those who
received single beta-blocker (BB) or calcium channel
blocker (CCB) (single BB/CCB group); and 4) those who
received multiple categories of medications (combin-
ation group). In this studied cohort, no patient received
other single agent therapy apart from RAASB, CCB, or
BB. A medication history was considered present when an
according category was prescribed as a maintenance medi-
cation for targeting blood pressure (BP) control within 6
months of allograft IgAN diagnosis.
Allograft IgAN and graft biopsy
Biopsies to confirm allograft IgAN were mostly performed
under the following clinical criteria: a progressive decline
in renal function, persistent hematuria, or significant pro-
teinuria of more than 1.0 g/day [7, 8]. Some patients
underwent protocol biopsies at time-zero and then again
2 weeks post-transplantation. The pathologic diagnosis of
allograft IgAN was confirmed when the specimens dem-
onstrated typical immunofluorescence pattern of IgA ± C3
staining in the glomerulus mesangial space.
Data collection
Patients’ clinical characteristics at the time of diagnosis for
allograft IgAN were collected, including age, sex, and the
relationship between the donor and recipient. Laboratory
values, including estimated glomerular filtration rate
(eGFR) using the CKD-EPI equation, dipstick albuminuria
(none or trace, 1+, or ≥ 2+), [21] and mean arterial pres-
sure (MAP, 1/3 of systolic BP plus 2/3 of diastolic BP)
were collected at the time of biopsy and after 6months.
As RAASB tends to be prescribed to those without pro-
gressive decline in graft function in view of its association
with acute kidney injury, we calculated the time-averaged
eGFRs during the first 3-month-period from allograft
IgAN diagnosis, in order to include this variable in our
multivariable analysis. The duration from transplantation
to allograft IgAN diagnosis was collected, considering that
allograft IgAN is a strong time-dependent event [8]. Infor-
mation on coexisting evidence of acute rejection was also
recorded from the pathology reports. Specialized patholo-
gists additionally reviewed the updated Oxford classifica-
tion, which showed clinical significance also in allograft
IgAN [20], in the pathology slides including; M (mesangial
hypercellularity), E (endocapillary hypercellularity), S (seg-
mental sclerosis), T (interstitial fibrosis or tubular atro-
phy), and C (cellular or fibrocellular crescent formation).
There were missing cases regarding the Oxford classifica-
tion because some slides were missing and some were at
insufficient quality for additional pathology review.
Study outcome
The main study outcome was 5-year DCGF. The follow-
up period was the duration from allograft IgAN diagno-
sis until DCGF outcome, follow-up loss, or 5 years.
DCGF was defined as a return to maintenance dialysis
or re-transplantation, and death events were censored.
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Statistical analysis
We presented categorical variables as frequencies (per-
centages) and continuous variables as median values
(interquartile ranges). The Kruskal-Wallis test was used to
compare continuous variables between the study groups,
and the chi-squared tests for the categorical variables. We
plotted Kaplan-Meier survival curves to demonstrate sur-
vival data, and the log-rank test was used to calculate the
p-values. The mixed effect model was used to investigate
whether usage of a single RAASB had significant inter-
action with changes in albuminuria or MAP at allograft
IgAN diagnosis and after 6months among those who
received antihypertensive medication. We used univariable
and multivariable Cox regression analysis to analyze
DCGF outcome, and the following variables were included
in the multivariable models, if not otherwise specified: age,
sex, CKD-EPI eGFR (categorical, < 15, ≥15 and 30, ≥30
and < 45, ≥45 and < 60, ≥60), albuminuria (none or trace,
1+, and ≥ 2+), mean arterial pressure (mmHg), and pres-
ence of acute rejection at the time of recurrence. In
addition, considering that a difference in longitudinal
clinical course might have been present among the studied
groups, additional multivariable model analysis was
performed, changing the eGFR value at baseline to the
time-averaged value within 3months from allograft IgAN
diagnosis. In the multivariable analysis testing the associ-
ation between the high-degree albuminuria after 6months
and the risk of DCGF in patients without prescribed anti-
hypertensive medications, the eGFR and MAP at 6
months were included in the multivariable model, instead
of values at baseline. Whether the presence of high-degree
albuminuria was a partial mediator with significance for
the association between the antihypertensive medication
subgroups and 5-year DCGF was tested using the “medi-
ation” package [22] in R (version 3.4.2, The R Foundation).
For the missing values, as they appeared in a random
manner, we performed multivariate imputation using clas-
sification and the regression trees method with the “mice”
package in R [23]. All other statistical analyses were also
performed with R. A two-sided p value of less than 0.05
was considered to indicate statistical significance.
Results
Study population
Of the 559 allograft IgAN patients, 464 patients were in-
cluded in the current study after exclusion criteria were ap-
plied (Fig. 1). Among them, 100 patients were determined
to have initial native IgAN as the cause of ESRD, and 11
had other kidney disease, suggesting possible de novo cases.
The other 353 patients had unknown primary etiology or
only clinical diagnoses for ESRD. Regarding antihyperten-
sive medication usage, there were 272, 38, 33, and 121
allograft IgAN patients in the no medication, single RAASB,
single BB/CCB, and combination groups, respectively.
Characteristics of the study population
Significant differences in baseline characteristics were
found between the study groups (Table 1). Although the
age and sex distributions were similar between
the groups, the single RAASB group had a significantly
longer duration from transplant to allograft IgAN diag-
nosis. This group had favorable clinical characteristics
regarding higher eGFR values and less frequent coexist-
ing acute rejection when they were diagnosed. On the
other hand, a substantially higher portion of patients in
the single RAASB group had albuminuria and hematuria
at baseline. Other medication usage, including tacroli-
mus prescription ratio among the used calcineurin in-
hibitors, steroid, or mycophenolic acid, did not differ
largely between the studied groups.
Risk factors for 5-year DCGF in the study population
The risk factors for 5-year DCGF in the study popula-
tion are shown in Table 2. Male sex, presence of T in
the Oxford classification, and impairment of kidney
function, as reflected by decrease in eGFR, were factors
prominently associated with an increased risk of DCGF.
Particularly, high-degree albuminuria after 6 months of
allograft IgAN diagnosis was associated with very high
risk for DCGF, which were even comparable to the cat-
egorical eGFR variable of < 30 or < 15 mL/min/1.73 m2.
Among those who did not require antihypertensive
medications, the degree of albuminuria at baseline was
not significantly associated with the risk of 5-year DCGF
(Additional file 1: Figure S1). However, those with per-
sistent albuminuria or who developed high-degree (≥2+)
albuminuria after 6 months demonstrated an increased
risk of 5-year DCGF. This association was significant
even after adjustment for age, sex, time from transplant-
ation to allograft IgAN diagnosis, and eGFR and MAP
values after 6 months (adjusted HR, 6.70 [1.51–29.76];
P = 0.01). Meanwhile, the presence of high MAP was not
significantly associated with 5-year DCGF in this patient
subgroup, suggesting the relative importance of the
high-degree albuminuria after 6 months.
By contrast, those who received antihypertensive medi-
cations following the diagnosis of allograft IgAN exhibited
worse prognosis than those who did not (Additional file 2:
Figure S2). Albuminuria and presence of high MAP dem-
onstrated a significant association with 5-year DCGF risk
in this patient group; however, baseline high-degree
albuminuria lost its significance in multivariable analysis
(adjusted HR, 1.31 [0.77–2.23]; P = 0.32). High-degree
albuminuria at 6 months remained a significant predictive
factor associated with 5-year DCGF in this subgroup (ad-
justed HR, 2.77 [1.56–4.90]; P < 0.001), also showing the
persistent high-degree albuminuria was an important risk
factor for DCGF.
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Blood pressure and urine dipstick albuminuria according
to antihypertensive medications
We analyzed whether differences were present in the
urine dipstick results of those with available values both at
the time of allograft IgAN diagnosis and after 6months
(Table 3). Compared to the other groups, the single
RAASB group had a lower portion of patients with persist-
ent albuminuria or who had developed high-degree
albuminuria after 6months. By contrast, the single BB/
CCB group had a higher portion of allograft IgAN patients
who developed high-degree (≥2+) dipstick albuminuria at
6months. Moreover, these differences in changes of albu-
minuria presence were significant (P for interaction =
0.03) with single RAASB usage even among those who
received single antihypertensive medications, showing that
RAASB may be better regarding albuminuria reduction
than other drug types.
In terms of blood pressure values, the median MAP
was the lowest in the single RAASB group; however, the
difference was not statistically significant (P = 0.09). In
fact, the MAP values became even more similar between
the studied groups after 6 months. The changes in high
MAP (> 100 mmHg) presence (P for interaction = 0.11)
or MAP values (P for interaction = 0.28) did not seem to
be affected by use of single RAASB. Therefore, we could
not identify a significant difference in blood pressure
control according to the antihypertensive medication
types.
DCGF according to antihypertensive medication
categories
Prognosis for DCGF was significantly different between
the studied subgroups (Fig. 2). Patients who did not re-
quire antihypertensive medications had the best prognosis,
as only 8/272 (2.9%) patients reached DCGF within 5 years
of their allograft IgAN diagnosis. The single RAASB group
demonstrated better outcome than the others, with 8/38
(21.1%) patients developing 5-year DCGF, compared to
15/33 (45.5%) and 52/121 (43.0%) in the single BB/CCB
and combination groups, respectively.
The above results were repetitively observed in our re-
gression analysis (Table 4). Compared to the single
RAASB group, the no medication group demonstrated
better prognosis, while the single BB/CCB and combin-
ation groups exhibited significantly worse prognoses.
Single BB/CCB usage and its association with worse
DCGF among single agent users remained valid when we
included the time-averaged eGFR values. When we
Fig. 1 Study population
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Table 1 Comparisons of baseline characteristics at the time of allograft IgAN diagnosis according to anti-hypertensive medication
prescription
No medication Single RAASB Single BB/CCB Combination
(N=272) (N=38) (N=33) (N=121)
Age at allograft IgAN Dx (years) 44 [34-50] 41 [36-47] 44 [32-54] 43 [35-51]
Male Sex 181 (66.5%) 22 (57.9%) 25 (75.8%) 83 (68.6%)
Duration from transplant to allograft
IgAN diagnosis (years)
3.8 [ 0.7- 7.5] 6.7 [ 3.2- 9.2] 5.4 [ 2.8- 8.1] 5.1 [ 2.0- 9.3]
Blood pressure (mmHg)
Systolic BP 129.0 [117.0-138.0] 120.0 [110.0-133.0] 120.0 [115.0-136.0] 129.0 [118.5-139.0]
Diastolic BP 78.0 [70.0-86.0] 74.0 [65.0-80.0] 78.0 [70.0-85.0] 80.0 [70.0-88.0]
MAP 94.3 [85.3-101.3] 84.8 [79.7-92.7] 93.0 [85.7-100.7] 94.3 [85.0-101.0]
Laboratory values
Serum creatinine (mg/dL) 1.7 [ 1.4- 2.0] 1.5 [ 1.2- 2.1] 1.9 [ 1.6- 2.6] 1.7 [ 1.4- 2.2]
eGFR (mL/min/1.73 m2) 45.0 [35.4-57.0] 50.9 [36.9-70.3] 38.0 [27.3-45.9] 45.1 [33.8-60.5]
Albuminuria
None or trace 189 (69.7%) 9 (23.7%) 20 (60.6%) 42 (35.0%)
1+ 27 (10.0%) 8 (21.1%) 7 (21.2%) 17 (14.2%)
=2+ 55 (20.3%) 21 (55.3%) 6 (18.2%) 61 (50.8%)
Hematuria 18 (6.6%) 18 (47.4%) 6 (18.2%) 41 (33.9%)
Other medication usage
Tacrolimus 138 (50.7) 16 (42.1) 20 (60.6) 51 (42.1)
Steroid 257 (94.5) 35 (92.1) 31 (93.9) 112 (92.6)
Mycophenolic acid 182 (66.9) 30 (78.9) 24 (72.7) 94 (77.7)
Donor characteristics
Age 39 [31-47] 36 [30-42] 40 [28-47] 40 [30-48]
Male sex 151 (55.5%) 21 (55.3%) 16 (48.5%) 61 (50.8%)
Type of donor
Living related 157 (57.7%) 24 (63.2%) 16 (48.5%) 72 (59.5%)
Living unrelated 60 (22.1%) 9 (23.7%) 12 (36.4%) 23 (19.0%)
Deceased 55 (20.2%) 5 (13.2%) 5 (15.2%) 26 (21.5%)
Pathological findings
Coexisting acute rejection 94 (34.6%) 5 (13.2%) 11 (33.3%) 33 (27.3%)
Oxford classification
Mesangial hypercellularity
M0 142 (81.6%) 23 (79.3%) 18 (81.8%) 56 (67.5%)
M1 32 (18.4%) 6 (20.7%) 4 (18.2%) 27 (32.5%)
Endocapillary hypercellularity
E0 130 (78.3%) 16 (57.1%) 16 (72.7%) 49 (59.8%)
E1 36 (21.7%) 12 (42.9%) 6 (27.3%) 33 (40.2%)
Segmental sclerosis
S0 108 (61.7%) 14 (48.3%) 16 (72.7%) 43 (51.2%)
S1 67 (38.3%) 15 (51.7%) 6 (27.3%) 41 (48.8%)
Tubular atrophy/interstitial fibrosis
T0 127 (72.6%) 21 (72.4%) 14 (63.6%) 56 (67.5%)
T1 33 (18.9%) 4 (13.8%) 4 (18.2%) 17 (20.5%)
T2 15 (8.6%) 4 (13.8%) 4 (18.2%) 10 (12.0%)
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divided subgroups according to the presence of confirmed
native IgAN, the inferiority for prognosis of single usage
BB/CCB when compared with prognosis of single RAASB
usage was shown only in allograft IgAN with unknown or
clinical cause for ESRD (hazard ratio 3.16, 95% confidence
interval 1.17–8.57, P = 0.02). On the contrary, in allograft
IgAN cases with confirmed native IgAN, the usage of
single BB/CCB showed non-significant difference regard-
ing prognosis with the single RAASB usage (hazard ratio
2.40, 95% confidence interval 0.44–13.08, P = 0.31). In
addition, within the combination group, the DCGF
prognosis did not significantly differ according to RAASB
usage (Additional file 3: Figure S3).
Finally, within the single RAASB group, DCGF was sig-
nificantly better in those without high-degree albuminuria
after 6months from diagnosis (P = 0.048) (Additional file 4:
Figure S4). Namely, allograft IgAN patients with high-de-
gree of albuminuria after 6months from their diagnosis
demonstrated poor prognosis, with a 5-year DCGF rate of
5/13 (38.5%). By contrast, only 3/21 (14.3%) single RAASB
users progressed to DCGF within 5 years in those without
high-degree albuminuria after 6months. Moreover, in our
mediation analysis, high-degree albuminuria after 6
months was a partial mediator of the association be-
tween the antihypertensive medication subgroups and
DCGF (P = 0.008).
Discussion
In this retrospective study, we investigated the potential
benefits of RAASB in allograft IgAN by identifying pre-
scribed hypertensive medication categories and compar-
ing the prognosis in terms of DCGF and changes in
albuminuria levels. Our main finding was that allograft
IgAN patients who received single RAASB demonstrated
better graft outcome than those who received single BB/
CCB or combination therapy. Among the single agent
users, single RAASB usage was associated with a signifi-
cantly reducing pattern of albuminuria. As the absence
of high-degree dipstick albuminuria after 6 months was
an important prognostic factor, benefits of RAASB on
DCGF might have been related to its protective effect on




Age (years) 1.00 (0.97–1.02) 0.71
Male sex (.vs female) 2.50 (1.46–4.28) <
0.001
Duration from transplant to allograft IgAN
diagnosis (years)
1.05 (0.98–1.12) 0.18
eGFR (.vs≥ 60 mL/min/1.73 m2)
≥ 45 and < 60 1.61 (0.68–3.82) 0.28
≥ 30 and < 45 2.35 (1.02–5.38) 0.04
≥ 15 and < 30 6.88 (2.94–16.14) <
0.001
< 15 7.43 (2.28–24.17) <
0.001
Albuminuria (.vs none or trace)
1+ at baseline 0.95 (0.43–2.10) 0.90
≥ 2+ at baseline 1.56 (0.86–2.83) 0.15
1+ at 6 months 1.81 (0.82–3.98) 0.14
≥ 2+ at 6 months 5.64 (3.20–9.93) <
0.001
MAP (mmHg)
High MAP (> 100mmHg) at baseline 1.12 (0.67–1.90) 0.66
High MAP (> 100mmHg) at 6 months 1.13 (0.72–1.77) 0.59
Coexisting acute rejection 1.07 (0.65–1.76) 0.80
Oxford classification
M1 (vs. M0) 1.09 (0.59–2.03) 0.78
E1 (vs. E0) 1.62 (0.89–2.98) 0.11
S1 (vs. S0) 1.36 (0.49–3.80) 0.52
T1 or T2 (vs. T0) 2.08 (1.21–3.55) 0.008
C1 or C2 (vs. C0) 1.50 (0.88–2.54) 0.13
DCGF Death-censored-graft failure, IgAN Immunoglobulin A nephropathy, eGFR
Estimated glomerular filtration rate, MAP Mean arterial pressure
aAdjusted with all variables in the table. When albuminuria or MAP after 6
months were included in the model, the values of eGFR, MAP, and the degree
of albuminuria at 6 months from diagnosis were included instead the baseline
values. Missing values were imputed using the multivariate imputation using
classification and the regression trees method
Table 1 Comparisons of baseline characteristics at the time of allograft IgAN diagnosis according to anti-hypertensive medication
prescription (Continued)
No medication Single RAASB Single BB/CCB Combination
(N=272) (N=38) (N=33) (N=121)
Cellular/fibrocellular crescents
C0 239 (87.9%) 30 (78.9%) 29 (87.9%) 88 (72.7%)
C1 30 (11.0%) 7 (18.4%) 4 (12.1%) 29 (24.0%)
C2 3 (1.1%) 1 (2.6%) 0 (0.0%) 4 (3.3%)
RAASB Renin-angiotensin-aldosterone system blockades, BB Beta blockers, CCB Calcium channel blockers, IgAN Immunoglobulin A nephropathy, eGFR Estimated
glomerular filtration rate, BP Blood pressure, MAP Mean arterial pressure
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Fig. 2 Kaplan-Meier survival curve showing death-censored graft failure according to the prescribed antihypertensive medication categories. The
x-axis indicates time from the diagnosis of allograft IgAN while the y-axis indicates cumulative survival
Table 3 Albuminuria and blood pressures at the time of diagnosis and after 6 months of allograft IgAN patients who had complete
information
At allograft IgAN diagnosis After 6 months
Dipstick albuminuria None or trace 1+ ≥2+ None or trace 1+ ≥2+
No medication (N = 216) 143 (66.2%) 22 (10.2%) 51 (23.6%) 166 (76.9%) 26 (12.0%) 24 (11.1%)
Single RAASB (N = 38) 9 (23.7%) 8 (21.1%) 21 (55.3%) 18 (47.4%) 7 (18.4%) 13 (34.2%)
Single BB/CCB (N = 28) 19 (67.9%) 5 (17.9%) 4 (14.3%) 15 (53.6%) 4 (14.3%) 9 (32.1%)
Combination (N = 94) 34 (36.2%) 10 (10.6%) 50 (53.2%) 33 (35.1%) 18 (19.1%) 43 (45.7%)
Blood pressure Systolic BP Diastolic BP MAP Systolic BP Diastolic BP MAP
No medication (N = 268) 129.0 [117.0–138.0] 78.0 [70.0–85.5] 95.0 [85.5–102.7] 125.0 [116.0–135.0] 76.0 [68.0–84.0] 92.7 [84.5–100.2]
Single RAASB (N = 33) 120.0 [110.0–133.0] 74.0 [65.0–80.0] 88.7 [81.7–98.7] 122.0 [118.0–136.0] 81.0 [72.0–88.0] 94.7 [90.0–103.3]
Single BB/CCB (N = 28) 120.0 [114.5–136.0] 79.0 [69.5–87.0] 93.2 [84.5–100.3] 126.5 [116.5–140.0] 79.0 [70.5–84.0] 94.2 [85.8–103.3]
Combination (N = 104) 129.0 [118.5–139.5] 80.0 [70.0–88.0] 96.3 [88.0–103.3] 128.0 [116.0–140.0] 79.0 [70.0–87.0] 93.7 [85.0–103.8]
IgAN Immunoglobulin A nephropathy, RAASB Renin-angiotensin-aldosterone blockades, BB Beta blockers, CCB Calcium channel blockers, BP Blood pressure, MAP
Mean arterial pressure
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urine albumin (a surrogate marker of urine protein) loss.
However, the result was only significant in the allograft
IgAN cases without confirmed native IgAN but was not
evident in the recurred IgAN cases in that IgAN was
also identified in native kidneys.
RAASB has been widely used for many renal diseases
because of its protective effect on the cardiovascular
and renal systems. The benefits of RAASB on renal
prognosis were well-demonstrated within proteinuric
primary glomerulonephritis or diabetic nephropathy pa-
tients [10, 11, 24, 25]. There is a possibility that the
medication may also be beneficial for graft outcome
after kidney transplantation; however, this has yet to be
confirmed [13–16]. In addition, while clinical guidelines
for kidney transplantation recipients suggest prescribing
RAASB for those with recurrent glomerulonephritis and
proteinuria [19], the recommendation level remains
low. Our study showed possible benefits of RAASB
usage as the initial single agent for better graft progno-
sis in allograft IgAN, which was not clearly indicated in
a previous report [18]. In addition to the preceding
study that showed RAASB’s protective effect on protein-
uria among allograft IgAN patients [17], our study also
demonstrated that the benefits may lead to better graft
survival.
As stated, this potential benefit might be related to the
identified medications’ protective effect on dipstick albu-
minuria, which is a surrogate marker of proteinuria [26, 27].
The reno-protective effect of RAASB is mainly derived from
reduced intraglomerular pressure and proteinuria, which
was considered to be independent of the underlying disease
[17]. In the present study, high-degree albuminuria after
certain period from the diagnosis of allograft IgAN was one
of the most important predictors of DCGF, while MAP or
baseline albuminuria demonstrated only weaker associa-
tions. This suggests that in a state of allograft IgAN, the
severity of glomerulonephritis, which may be reflected by
persistent albuminuria, may be an important parameter or
damaging factor for worse graft prognosis. Considering the
close linkage between single RAASB usage, decreased pro-
portion of patients with high-degree albuminuria, and better
DCGF, albuminuria reduction might be the moderator of
the association between RAASB and better graft outcome
among single agent users. In addition, this may also be
supported by the fact failure to reduce albuminuria during
the first 6months from allograft IgAN diagnosis, even
within the single RAASB group, was associated with
worse allograft outcome. Clinicians should keep this
result in mind and consider RAASB when single-agent
antihypertensive therapy is required for allograft IgAN
patients; however, they should also consider the side
effects with caution [14, 28].
Still, it should be noted that the possible benefits of
single agent RAASB over single BB or CCB was not con-
firmed herein for the recurred IgAN cases with confirmed
native IgAN. In our previous study, the clinical signifi-
cance of the Oxford classification was different according
to allograft IgAN subtypes [20]. In allograft IgAN with
confirmed native IgAN cases, M, E, S, and C components,
which may reflect intraglomerular disease activity, were
important prognostic parameters, but in the cases without
confirmed native IgAN, only the T was a significant
pathologic risk factor. When relating this with the current
study results, appropriate immunosuppression may be
more important in the “recurred IgAN” cases, which
showed more rapid progression and in which pathologic
parameters related to intraglomerular disease activity
showed prognostic importance. On the other hand, in
allograft IgAN cases without confirmed native IgAN,
which were possibly de novo ones in which progressed
tubular injury, the T, was an important prognostic factor,
reduction of proteinuria to decrease progressive allograft
injury might have been more important than in recurred
IgAN cases. Our study suggests a future study investigat-
ing whether actual pathophysiology of recurred IgAN and
de novo IgAN is different. Moreover, studying whether
usage of immunosuppression is associated with difference
in prognosis of recurred IgAN cases, particularly with
high-risk pathologic parameters, may help developing
individualized treatment strategy for allograft IgAN.
Patients who did not require antihypertensive medica-
tion following allograft IgAN diagnosis demonstrated
Table 4 Use of HTN medication within 6 months from allograft IgAN Dx and its’ association with the risk of DCGF
Univariable Multivariable – model 1a Multivariable – model 2b
HR (95% CI) P Adjusted HR (95% CI) P Adjusted HR (95% CI) P
Single RAASB Ref. Ref. Ref.
No medication 0.15 (0.06–0.40) < 0.001 0.17 (0.06–0.48) 0.001 0.17 (0.06–0.49) 0.001
Single BB/CCB 2.74 (1.16–6.47) 0.02 3.05 (1.19–7.79) 0.02 2.88 (1.13–7.37) 0.03
Combination 2.76 (1.32–5.79) 0.007 2.72 (1.24–5.96) 0.01 2.28 (1.04–4.99) 0.04
HR Hazard ratio, CI Confidence interval, RAASB Renin-angiotensin-aldosterone system blockades, BB Beta blockers, CCB Calcium channel blockers
aModel 1. Adjusted for clinicopathologic characteristics at the time of allograft IgAN; age, sex, CKD-EPI eGFR (categorical, < 15, ≥15 and 30, ≥30 and < 45, ≥45
and < 60, ≥60), albuminuria (none or trace, 1+, and ≥ 2+), mean arterial pressure (mmHg), pathologic components of the Oxford classification (M, E, S, T, and C
components), presence of acute rejection at the time of recurrence
bModel 2. The adjustment variable of eGFR value at allograft IgAN diagnosis in above Model 1 was substituted for time-averaged eGFR within 3 months after
diagnosis of allograft IgAN
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better prognosis than those who did. By contrast, those
who received combination therapy displayed poorer prog-
nosis, regardless of the prescription of RAASB. A required
medication dosage or the presence of uncontrolled BP
might have been the more important parameter related to
graft prognosis than the albuminuria in these patients.
Furthermore, this implies that the benefit of RAASB usage
in advanced allograft IgAN requiring multiple antihyper-
tensive agents remains unclear. Therefore, the current
study only supports the usage of RAASB when single-
agent therapy is required.
Several unresolved limitations should be considered in
our study. These are mainly related to the difficulty of
conducting a study concerning post-transplant medication
usage, especially for non-rejection allograft diseases. First,
a hidden confounding effect might be present. It is true
that clinicians may hesitate to prescribe RAASB in pa-
tients with rapidly declining graft function. Although we
studied the long-term outcomes and attempted to adjust
the potential confounders, this innate difference in antihy-
pertensive medication indications might have affected our
results. Second, as many patients were receiving combin-
ation therapy, a comparison between the single agents,
which would give the most important consequence, was
performed only in a limited number of patients. However,
as this was one of the largest cohorts of allograft IgAN to
date, this might be the only reported evidence that may
demonstrate the possible benefits of RAASB usage on
graft survival in allograft IgAN. Third, due to the study’s
retrospective nature, whether the addition of RAASB in
allograft IgAN patients is necessary could not be directly
answered herein. In addition, several patients were already
on RAASB, and a sufficient wash-out period could not
have been secured. While a prospective study may be ne-
cessary to solve this problem, the inclusion of sufficient
number of trial subjects may be an issue. Lastly, we used
dipstick albuminuria values, a surrogate marker of pro-
teinuria [21], and amounts of proteinuria were not mea-
sured using the 24-h collection or random urine protein/
creatinine ratio. Although this is a significant limitation,
the use of the variable was necessitated by the limited
number of allograft IgAN patients with available quanti-
fied proteinuria results.
Conclusions
The potential benefit of RAASB on allograft IgAN prog-
nosis was highlighted in the present study. Clinicians may
consider using RAASB for allograft IgAN cases without
confirmed native IgAN, or de novo cases, particularly in
those at an early stage who do not require combination
therapy. Additional studies regarding the treatment strat-
egies for primary glomerulonephritis in renal transplant
recipients are warranted.
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